Cargando…
Targeting Huntington’s disease through histone deacetylases
Huntington’s disease (HD) is a debilitating neurodegenerative condition with significant burdens on both patient and healthcare costs. Despite extensive research, treatment options for patients with this condition remain limited. Aberrant post-translational modification (PTM) of proteins is emerging...
Autor principal: | Gray, Steven G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3365382/ https://www.ncbi.nlm.nih.gov/pubmed/22704341 http://dx.doi.org/10.1007/s13148-011-0025-7 |
Ejemplares similares
-
Targeting histone deacetylases for the treatment of disease
por: Lawless, M W, et al.
Publicado: (2009) -
The Effects of Selective Inhibition of Histone Deacetylase 1 and 3 in Huntington’s Disease Mice
por: Hecklau, Katharina, et al.
Publicado: (2021) -
The Effects of Pharmacological Inhibition of Histone Deacetylase 3 (HDAC3) in Huntington’s Disease Mice
por: Jia, Haiqun, et al.
Publicado: (2016) -
Histone deacetylases as targets for antitrypanosomal drugs
por: Zuma, Aline A, et al.
Publicado: (2018) -
Histone Deacetylases as Epigenetic Targets for Treating Parkinson’s Disease
por: Li, Yan, et al.
Publicado: (2022)